|

CP-383 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Tasca Therapeutics1

Indications

  • Pancreatic Cancer, Advanced or Metastatic1
  • Head and Neck (HNSCC)1
  • Solid Tumor Malignancies1
  • Small Cell Lung Cancer (SCLC)1
  • Colorectal Carcinoma1

Denver, Colorado1 trial

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Sarah Cannon Research Institute at HealthONE

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.